Oncolytic Viruses in the Therapy of Lymphoproliferative Diseases

P O Vorobyev; F E Babaeva; A V Panova; J Shakiba; S K Kravchenko; A V Soboleva; A V Lipatova

doi:10.1134/S0026893322050144

Oncolytic Viruses in the Therapy of Lymphoproliferative Diseases

Mol Biol. 2022;56(5):684-695. doi: 10.1134/S0026893322050144. Epub 2022 Oct 5.

Authors

P O Vorobyev¹, F E Babaeva², A V Panova³, J Shakiba⁴, S K Kravchenko², A V Soboleva¹, A V Lipatova¹

Affiliations

¹ Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia.
² National Medical Research Center for Hematology, Ministry of Health of Russia, 125167 Moscow, Russia.
³ Vavilov Institute of General Genetics, Russian Academy of Sciences, 117971 Moscow, Russia.
⁴ Moscow Institute of Physics and Technology, 141701 Dolgoprudny, Russia.

Abstract

Cancer is a leading causes of death. Despite significant success in the treatment of lymphatic system tumors, the problems of relapse, drug resistance and effectiveness of therapy remain relevant. Oncolytic viruses are able to replicate in tumor cells and destroy them without affecting normal, healthy tissues. By activating antitumor immunity, viruses are effective against malignant neoplasms of various nature. In lymphoproliferative diseases with a drug-resistant phenotype, many cases of remissions have been described after viral therapy. The current level of understanding of viral biology and the discovery of host cell interaction mechanisms made it possible to create unique strains with high oncoselectivity widely used in clinical practice in recent years.

Keywords: clinical trials; lymphoproliferative diseases; oncolytic viruses; spontaneous remission; virotherapy.

© Pleiades Publishing, Inc. 2022, ISSN 0026-8933, Molecular Biology, 2022, Vol. 56, No. 5, pp. 684–695. © Pleiades Publishing, Inc., 2022.Russian Text © The Author(s), 2022, published in Molekulyarnaya Biologiya, 2022, Vol. 56, No. 5, pp. 751–763.